CyPath Lung Unit Sales Soar 146% YoY in Q1, Boosting bioAffinity's Commercial Momentum
BIAF has more than doubled off its 52-week low of $0.693.
Summary
bioAffinity Technologies announced a substantial 146% year-over-year increase in CyPath Lung unit sales for Q1 2026, based on preliminary unaudited data. This significant growth for their noninvasive lung cancer diagnostic follows the company's recent 2025 10-K filing (March 16, 2026), which included a 'going concern' warning due to a net loss and short cash runway, despite acknowledging core product revenue growth. The accelerating commercialization momentum, as evidenced by these Q1 sales figures, is a material positive development for the micro-cap company, potentially mitigating some of the financial risks highlighted in its annual report. Traders will be closely watching for the full Q1 earnings report to confirm these preliminary figures and for updates on the company's cash position and progress on its planned longitudinal study.
At the time of this announcement, BIAF was trading at $3.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.9M. The 52-week trading range was $0.69 to $46.53. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.